For anyone not following this stock, this week is pivotal as the results of a year or so’s work are due before the AGM. Essentially they have applied the drug to the eyeballs of monkeys to see if it will have the desired effect in the retinal layer that is problematic in Retinitis Pigmentosa type 11, some 4000 people in the western world have this condition and will go blind in their 4the decade approx. The drug if successful will prevent this condition and these meds usually are sold for around 25000 per annum as approved by the FDA. The Lions eye institute already have the client list, so, its just got to get thru the trials and it will have a ready market. Experts put the probability of success of this at 70% if the histopath is a pass ( proving there is no build up in the retina of the waste material). Do the maths. A previous poster suggested a 14x uplift in fair value, if we were to get a third of that with this current round of results(when we should get over half) it would see the sp jump 4x or so. There are also 3 more drugs in the pipeline and the platform validation that will accompany the first drugs passage into the clinic.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)